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PREFACE 
The dissertation as part of the MMED is organized into two main chapters.
Chapter 1 – It is a preamble and review of literature pertinent to the topic, background
of  the  problem  and  burden  of  CKD  in  South  Africa.  The  mechanisms  and
pathophysiology of vascular calcification are also explored. Ethnic variations in bone
mineral metabolism are reviewed. Concepts and theories regarding survival advantage
and impact on mortality among Blacks and non-Blacks counterparts with ESKD is
revised.  Most  of  the  studies  were  conducted  in  Europe  and North  America.  This
identified a void which helped in providing the rationale for the study. 
Chapter 2 -is presented as a manuscript ready for submission to BMC Nephrology. 
The Abstract and Chapter 2 are presented in a format following the policies and 
guidelines as per Editorial Board Guidelines. Chapter 2 is expected to be submitted 
for publication.
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ABSTRACT
BACKGROUND
Vascular calcification is a major risk factor for cardiovascular morbidity and mortality in
patients  with  end  stage  renal  disease  (ESRD).  In  Western  countries,  Blacks  with  ESRD
appear to have lesser degrees of vascular calcification compared to non-Blacks. However,
there is no published data on the association of ethnic differences in vascular calcification and
survival in ESRD from Sub-Saharan Africa.
METHODS 
This study assessed the 5-year change in vascular calcification and mortality in a previously
published cohort of patients with ESRD. Vascular calcification was assessed by abdominal
aortic calcification score (lateral abdominal radiograph) and vascular stiffness by pulse wave
velocity. 
RESULTS
Sixty-six of the original 74 participants, studied a baseline, were identified. The median age
was 46.6 years (37.6-59.2) and 57.6% were women. Abdominal aortic calcification showed
no progression among Blacks [baseline range 0-5, follow up range 0-8 (p=1.00)], but a non-
significant trend to progression among non-Blacks [baseline range 0-19, follow up range 0-22
(p=0.066)]. Black participants did not display a survival advantage (p=0.870).  Overall, sepsis
was the most common cause of mortality (64% of those with an identifiable cause of death).
Non-Blacks had higher parathyroidectomy rates than Blacks with 9/30 cases compared to
2/36 (p=0.036). After adjustment for parathyroidectomy at follow up, the odds ratio of having
abdominal  vascular  calcification  score  of  ≥1  amongst  non-Blacks  was  8.6-fold  greater
compared  to  Blacks  (p=  0.03).  Central  aortic  systolic  pressures  (CASP)  and  pulse  wave
velocities (PWV) were higher in the study population than age matched normative values. At
follow up, a positive correlation (r=0.3) was observed between PWV and abdominal aortic
calcification (p=0.04). Elevated baseline coronary artery calcification score and FGF-23 level
at baseline were not associated with a difference in mortality. 
CONCLUSION
There was no significant progression in vascular calcification among Blacks.  After adjusting
for  increased  parathyroidectomy  rates,  there  was  a  greater  progression  of  vascular
calcification amongst non-Blacks compared to Blacks highlighting possible ethnic differences
in calcium phosphate metabolism in patients with ESRD. The lack of vascular calcification
progression in Blacks was not however associated with improved survival, but the sample size
was small.
KEYWORDS 
vii
Chronic  kidney  disease,  dialysis,  vascular  calcification,  vascular  stiffness,  pulse  wave
velocity, FGF- 23
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INTRODUCTION
INTRODUCTION
Background of the Problem
With the increasing burden of end stage renal disease (ESRD) there is a consequent
growing demand for renal replacement therapy1,2,3. A population based sample study
done in Bellville, Cape Town showed a very high prevalence of CKD  4. Using the
Modification of Diet in Renal Disease (MDRD) to calculate the GFR, the prevalence
of CKD stage 3 to 5 was 7,6% and 23.9 % respectively with and without correction
for ethnicity 4. In Sub Saharan Africa, the number of deaths from CKD have risen by
82% in 2008 compared to 19905. Globally, end stage renal disease (ESRD) has had
the third largest increase in mortality rate behind HIV/AIDS and diabetes 5. Of great
concern is the higher cardiovascular mortality among patients requiring dialysis which
include sudden cardiac death due to ventricular dysrhythmias, myocardial infarction,
heart failure and peripheral vascular diseases  5, 6. The National Kidney Foundation's
Task Force on Cardiovascular Disease (CVD) in Chronic Renal Disease in United
States in 1998 demonstrated that patients on hemodialysis had an approximately 10 to
30  fold  greater  CVD  mortality  rate  compared  to  the  general  population  after
stratification for race, sex and age  7. It is thought that the heavy burden of vascular
calcification involving the tunica media of blood vessels leads to arterial stiffness and
calcification  in  the  intima  results  in  a  predilection  towards  formation  of
atherosclerotic plaques and consequent cardiac disease8. Vascular disease in ESRD is
further accelerated by altered metabolism of parathyroid hormone (PTH), calcium,
phosphate and vitamin D levels which induce mediators of bone like metabolism and
mineralization in the tunica media 9. 
Vascular Calcification 
Vascular Calcification Pathophysiology
Vascular  Calcification  pathogenesis  is  not  fully  understood and  is  believed  to  be
multifactorial10.  Various  pathogenic  mechanism have been studied  and proposed10.
2Several  studies  have  identified  the  link  between  both  traditional  risk  factors  and
uremic  specific  risk  factors  in  the  association  between  vascular  calcification  and
CKD11,12. Previously, vascular calcification was considered as a passive mechanism 13.
However, research in the last decade has shown that it is actually an active process
involving ossification of vascular structures in which different factors are involved in
the deposition of the calcium phosphate product in the extracellular matrix14,15. Several
factors are expressed during vascular calcification which include bone-related proteins
such as type I collagen, osteopontin, bone morphogenetic protein-2, bone sialoprotein
and alkaline phosphatase showing that it is a highly regulated active cellular process16.
Vascular calcification within arteries occurs in several ways, as: dispersed, very small
hydroxyapatite crystals, large calcified deposits and mineralized cartilage and bone-
like tissue containing marrow  17.  Several in-vitro studies have shown that vascular
smooth muscle cells (VSMC) and pericytes demonstrate characteristics of osteoblasts
lineage cells if cultured within a medium mimicking ESRD 9. In cell cultures VSMC
and pericytes have shown the ability to produce similar bone forming transcription
factors and proteins and is induced by high concentration of oxidized lipids cytokines,
uremic serum, phosphorus, high glucose, and other yet to be discovered factors 9,18. 
Osteoblasts  and  VSMC  derive  from  similar  mesenchyme  precursor  cell  10.  Core
binding  factor  alpha  (Cbfa1),  which  is  heterodimeric  osteogenic  differentiation
transcription factor  19 is thought to be switched on by high levels of phosphate and
uremic specific toxins which turns the VSMC into an osteoblast  18,20  . Jono et al  20
demonstrated that VSMC calcify in the presence of beta glycophospherate, a donor of
phosphate,  with  increased  regulation  of  Cbfa1.  Cbfa1  downstream  proteins
Osteopontin and Type  1 collagen were also found expressed with Cbfa1 in intimal
and medial calcification from CKD patients leading to differentiation of VSMC to
osteoblast like cells 10. 
Run X2 an osteogenic transcription factor that promotes osteogenic differentiation of
vascular  smooth  muscle  cells  is  induced  by  high  calcium/phosphate,  parathyroid
hormone, Fibroblast  Growth Factor 23 (FGF 23) and increased oxidative stress in
CKD  patients  21.  Run  X2  induces  RANKL  expression  in  VSMC which  enhance
directly  VSMC calcification  also  contributes  to  bone  resorption  in  CKD  patients
through bone resorbing osteoclasts 21.In addition to promotion of differentiation, Run
3X2 strongly promotes the expression of type 1 collagen and upregulates expression of
VEGF 22. VSMC expressing RANKL upregulates migration, production of cytokines
and osteoclast formation of macrophage accelerating vascular calcification 21. 
Hyperphosphatemia also plays an important part in vascular calcification. Giachelli 23
showed that increase in phosphate plays an important part in promoting the vascular
phenotype VSMC to osteogenic phenotype predisposing to vascular calcification. The
induced  changes  by  phosphate  include  upregulated  expression  osteogenic  markers
osteocalcin and Cbfa1 genes which seem to occur after exposure elevated phosphate
levels exposure 23. 
Moustapha et al  24 showed that  elevated homocysteine levels poses an independent
risk  factor  for  CVS   mortality  and  morbidity  in  ESKD.  Homocysteine  in  an
atheromatous plaque and its ability to stimulate osteogenic cell differentiation partly
explains its link with atherosclerosis 25.
FGF 23 discovery  has  altered  our  conceptualization  of  CKD – mineral  and bone
disorder  (MBD)  26 .  Complex  interactions  have  been  revealed  which  include
interactions, hormonal feedback loops with the kidney, intestine, bone and parathyroid
glands  26.  In  the  past  decade,  studies  have  shown the  links  between FGF 23 and
cardiovascular events  26,  27. FGF 23 is secreted by osteoblasts and osteoclasts in the
bone  to  the  bloodstream  where  it  acts  as  a  phosphaturic  hormone  28,  29.  FGF  23
requires α Klotho, a membrane  co-receptor to induce specific signaling pathways30,31.
α Klotho is highly expressed in the kidneys and parathyroids 26. FGF 23 primary target
of is α Klotho- FGF 23 receptor complex which induces urinary phosphate excretion
by  decreasing  expression  of  type  2a  and  2c  sodium  dependent  phosphate  co
transporters  (NPT2a  and  NPT2c)  in  the  renal  proximal  tubule  32.  FGF  23  also
decreases intestinal absorption of phosphate by inhibiting the renal expression of 1 α
hydroxylase and stimulating the catabolic effects of 24 hydroxylase  33. FGF 23 has
also been shown to target parathyroid hormones but  the molecular regulation of its
synthesis is not clearly defined 34.  
FGF 23  increases in CKD with decline in kidney function such that at ESRD, FGF 23
levels are sometimes more than 1000 fold above normal range 35. The increase is to
compensate for phosphate retention in order to promote phosphaturia 36. As the GFR
declines, the kidney has diminished ability to excrete phosphate resulting in phosphate
4accumulation  despite  high  levels  of  FGF 23  35,37.  The  supraphysiological  FGF 23
levels have been associated with significantly high mortality risk during dialysis  38
39.When directly compared with phosphate and PTH, FGF23 has been shown to be the
strongest  predictor  of  adverse  outcomes40  Several  studies  have  shown a  relation
between FGF 23 and Left Ventricular Hypertrophy (LVH)41,42. FGF 23 is believed to
induce cardiac myocytes hypertrophy via Phosphoinositide-specific Phospholipase C
(PCL) – γ signaling dependent of FGF receptor activation independent of α Klotho26
Inhibitors of Vascular Calcification
Numerous factors are involved in the inhibition of vascular calcification these include:
1. Matrix Glutamate Protein (MGP)
MGP is  a vitamin K-dependent γ-carboxylated protein available in vascular smooth
muscle and bone 43. Medial vascular calcification is observed among rats on treatment
with a vitamin K antagonist warfarin 44. Humans with a mutant form of MGP (Keutel
Syndrome) develop medial calcification although not severe suggesting that MGP is
an inhibitor  of  calcification  17,45.  Higher  rates  of  vascular  calcification  is  observed
among CKD patients on warfarin because of the blockage of γ carboxylation of MGP
by warfarin 46. There is an association of both aortal stenosis and excessive vascular
calcification with Warfarin therapy on patients with ESRD 47. 
2. Fetuin A
Serum Fetuin-A an α2-Heremans Schmid glycoprotein (AHSG) is  encoded by the
AHSG gene dominantly expressed in the liver 48. Serum Fetuin A inhibits the de novo
formation  of  calcium  phosphate and  deficient  mice  develop  widespread  tissue
calcification in the kidney, myocardium lung, skin and tongue 49. Patients on dialysis
have  low  Fetuin  A  levels  which  are  observed  to  be  associated  with  elevated
calcification of vessels and a higher risk of CVS morbidity and mortality 50. 
Pyrophosphate 
Pyrophosphate acts as an endogenous inhibitor of vascular calcification by inhibiting
hydroxyapatite  6.  In  ESRD,  plasma  levels  of  pyrophosphate  are  low  correlate
inversely with vascular calcification 6.
5Osteopontin
Speer  et  al51 and  others  have  reported  that  osteopontin  levels  are  elevated  at
calcification  sites  in  atherosclerotic  plaques  in  uremic  arteriopathy,  diabetic
vasculopathy, native and prosthetic valves but not in normal arteries 52,-46. Osteopontin
is an acid phosphatase found normally in mineralized tissue like bone and teeth 51. It is
thought that Osteopontin promotes osteoclastic function through the αvβ3 integrin and
also inhibits apatite growth 23. 
Types of Vascular Calcification
Calcification tends to occur at different sites including the: vascular intima and media,
soft tissue, cardiac vasculature and over the mitral and aortic valves.17. 
Intimal Calcification
Inflammation,  thickening  and  calcification  of  the  intimal  layer  is  called
atherosclerosis 53. Atherosclerosis occurs when lipid laden macrophages are trapped in
the sub-endothelial layer forming lipid laden plaques in tunica intima of the arteries
resulting  in  micro  inflammation  of  the  atherosclerotic  plaque  53.  Lamellar  bone
formation, osteogenesis and osteoblast induction is evident as the atheromatous lesion
progresses 54. The distribution of atherosclerosis is patchy, focal affecting the medium
sized arteries such as the epicardial  coronary, carotid,  iliac and femoral arteries  55.
Muscular  arteries  such as  the  internal  mammary  and  radial  are  spared  55.  Tunica
intima vascular calcification is associated with lipid-laden atherosclerotic plaques that
are flow-limiting and mainly occurs at arterial branch points increasing the risk of
acute coronary syndromes 55,56.
Diagrammatic representation showing the difference between medial and intimal 
calcification.
A cross section of an arterial wall  
Sinha et al 200817
6Medial Calcification
Medial  calcification  also  known  as  Monckeberg  sclerosis  occurs  when
circumferentially  amorphous mineral   forms within or along elastic  lamelle  of the
tunica media 54. A simplified suggested pathogenesis of medial calcification is shown
below
Figure 2 - Diagrammatic representation of pathogenesis of medial calcification 
Lanzer et al 47
Calcium phosphate nanocrystals are endocytosed or deposited on extracellular matrix
elastin fibers  47. Namocrystals endocytosed are dissolved at low pH and calcium is
released into the cytoplasm 47. Osteochodrotic transdifferentiation or cellular death of
VSMC or pericytes occurs after a rise in calcium levels  47.  Medial calcification of
arteries is observed among renal and diabetic aging populations 53,57. Predominantly it
occurs in large arteries and tributaries 58. Medial calcification tends occur in younger
patients compared to intimal calcification in CKD, but are also more likely to have a
prolonged hemodialysis history increasing the possible time for calcification 59 
Calciphylaxis/Calcific Uraemic Arteriolopathy (CUA)
Calciphylaxis is formed by arteriolar medial calcification associated with occlusive
thrombotic cutaneous ischemia, tissue death leading to ulceration, secondary infection
and  high  mortality  rates  60.  The  full  pathophysiology  of  calciphylaxis  is  poorly
7understood  60.  Intimal  fibrosis  and  medial  calcification  of  superficial  arterioles
coupled  with  occlusive  thrombosis  resulting  in  skin  ischemic  necrosis  occurs  in
calciphylaxis 61.
Valvular Calcification
Increased  Asymmetric  Dymethyl  Arginine  (ADMA),  Reactive  Oxygen  Species
(ROS), hyperphosphatemia, and elevated expression of Receptor Activator of Nuclear
Kappa Ligand (RANKL) act as promoters of calcific valve degeneration in patients
with ESRD  62. Lower circulating Fetuin A levels and MGP activation of also favor
valvular calcification 62.
The Link: Pulse Wave Velocity, Vascular Calcification and Mortality. 
An important link exists between pulse wave velocity (PWV), vascular calcification
and CVS mortality and morbidity. Vessel stiffness due to vascular calcification can be
assessed noninvasively using PWV which is the velocity of the pulse wave to travel a
given distance between two sites of the arterial system  63.  Vascular stiffness can be
measured by PWV which translates to a higher velocity as the blood vessel stiffens 64.
Temmar et al 65 showed that patients with CKD had a higher PWV, regardless of CKD
stage  compared  to  controls  with  preserved  kidney  function.  Patients  with  ESRD
elevated vascular stiffness,  determined by aortic  PWV measurement,  was a robust
predictor of all cause, CVS morbidity and mortality  63.  Decreased elasticity due to
contributory factors as calcification of vessel walls , atherosclerosis, uremia, changes
in  vessel quantities of collagen and elastin in CKD results in arterial stiffness 9,59,61. 
LVH and its ensuing complications, is a significant cause of mortality and morbidity
among CKD 5D patients 26, 66,  67. LVH is of poor prognostic significance because it is
an independent risk factor for arrhythmia development, ischemic heart disease,sudden
heart failure and cardiac death  67. LVH in CKD is both secondary to pressure and
volume overload 67. PWV which is now being widely accepted as the ‘gold standard’
for arterial calcification can be used as a non-invasive way to measure the pressure
overload  in  CKD 5D patients  67,68,69.  The  pressure  overload  is  secondary  to  prior
existing hypertension, loss of vessel pliability due to lack of elasticity and to vascular
calcification  resulting  in  augmented  pulse  pressure  67,70.  Vessel  stiffness  results  in
increased oxygen consumption and reduced cardiac perfusion pressure 67. A supply –
8demand  imbalance  occurs  resulting  in  reduced  coronary  reserve  and  myocardial
ischemia (fig1) 67 . 
Fig 1
Taddei et al 67
Patients with CKD 5D are in a volume and pressure overload states. A combination of
CKD 5D factors  and  sustained  overload  features  such  as  long  standing increased
systolic  blood  pressure,  activation  of  the  RAAS  system  and  anemia  results  in
maladaptive LVH causing a uremic cardiomyopathy 71-72. Certain maladaptive changes
of myocytes including accumulation of collagen, myocyte death, calcification, fibrosis
are observed in uremic cardiomyopathy causing systolic and diastolic dysfunction 73.
Patients with uremic cardiomyopathy are predisposed to sudden cardiac death due to
electrical instability, cardiac failure and reentry tachy - arrythmias 74.
Spectrum of Cardiovascular Disease in CKD
In  CKD,  nontraditional  and  traditional  risk  factors  are  both  involved  in  the
progression of CVS disease 75. Traditional risk factors include those used to calculate
the  Frimingham  Heart  Score  in  predicting  coronary  artery  disease  in  the  general
population  76.  Cardiovascular  disease  pathophysiology  in  CKD  5D  includes
arteriosclerosis, atherosclerosis, coronary artery disease, LVH associated with sudden
cardiac  death  from arrhythmias  and  electrolyte  abnormalities  77.  Current  evidence
suggests that the severity and aeitiology of atherosclerosis  in CKD patients differs
from that  in  the general  population  78.  Knowledge of these differences  provides  a
reasoning for identification of treatment and prevention strategies for the management
of high burden of CVD in patients with CKD 77. Weiner et al 79 demonstrated the poor
overall  accuracy  of  the  Framingham  instrument  in  predicting  cardiac  events  in
individuals with CKD and advocated for CKD specific equation.
9Observed  nontraditional,  uremic  related,  risk  factors  that  worsens  as  the  kidney
function declines contribute to the higher risk of CVD observed in CKD patients 5,80.
The  risk  factors  include  anemia,  arteriosclerosis,  atherosclerosis,  fluid  volume
overload,  endothelial  dysfunction,  abnormal  calcium,  Vitamin  D,  phosphate
metabolism  and  many  more75.  Dialysis  patients  are  a  heterogeneous  group.  The
pathophysiology  and  dimensions  of  cardiovascular  disease  differs  markedly  77.
Atherosclerosis is only part of the jig saw puzzle of arterial disease in patients with
CKD 5D 77. 
In patients on dialysis who have normal cholesterol levels, the  treatment with statins
in the primary prevention of CVD needs to be investigated further  77. Three large,
randomized,  placebo-controlled trials  of different  statins  were done in the dialysis
population  which  were  the  4D German Diabetes  Dialysis  Study  81,  AURORA (A
Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis. An
Assessment of Survival and Cardiovascular Events)  82 and SHARP (Study of Heart
and Renal Protection) studies83. Results from these studies show that there is a limited
role  of  statins  in  patients  undergoing  hemodialysis  and  peritoneal  dialysis,  this
highlights a different spectrum of risk factors in CKD patients 77. 
Ethnic Variations in Vascular Calcification and Mortality of CKD 5D 
In mineral metabolism, ethnicity plays a vital role 84. Fracture risk and osteoporosis is
different in various ethnicities 85. African descendants in the United States have higher
bone density and fewer fractures than their Caucasian and Hispanic counterparts 85,86.
Variations in ethnic mineral metabolism of calcium homeostasis, 25-hydroxy vitamin
D serum levels, PTH with bone acquisition structure are observed 87. 
The  Multi  Ethnic  Study  of  Atherosclerosis  (MESA)  showed  significant  coronary
calcification  in  Caucasians  compared  to  their  Black  counterparts  which  was  not
explained  by  the  traditional  coronary  risk  factors  88.  Whether  coronary  artery
calcification  increases  the  risk  of  adverse  outcomes  in  ESRD  is  an  important
unanswered question  89. Wilkeinson et al  90 showed that elevated coronary calcium
scores   in  patients  with  ESRD  has  a  propensity  to  predict  CVS  mortality  and
morbidity but effects were attenuated after age adjustment. A multicenter randomized
trial  done  by  Kraus  et  al  91 of  the  prevalence  of  vascular  calcification  in  ESRD
patients on hemodialysis showed that the prevalence of aortic vulvular calcification
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was higher  among whites  compared to other  races.  African Americans also had a
lower prevalence of mitral  annulus calcification compared to Caucasians and other
races 91. Interestingly radiologically, significant fewer Whites did not have abdominal
aortic  calcification  than  African  Americans91.  Proportionally,  more  Whites  had
abdominal  aortic  calcifications  in  the  ‘significant’  category   91.  Ethnic  differences
have  also  been  described  for  the  metabolism of  calcium  and  phosphate  affecting
extracellular calcium- phosphate nanocrystal formation during the initial process of
vascular  calcification  87.Black  individuals  have been shown to have lower urinary
excretion,  increased intestinal absorption of calcium, reduced levels of 25 hydroxy
vitamin D and increased levels of 1, 25 hydroxy vitamin D and parathyroid hormone
92,93,94. The body phosphorus concentration is higher in blacks than whites 95. Mineral
density,  bone architecture  and bone mass  is  better  in  blacks  96.  These  differences
confer  an  advantage  to  blacks  who  have  stronger  bones,  fewer  cardiovascular
calcification and fewer risk of fracture 47, 97.
Further,  Blacks  seem  to  have  a  survival  advantage  in  the  ESRD  population
undergoing dialysis  98.  There  have  been  many  factors  attributed  to  the  survival
advantage of blacks which include: a lower pro- inflammatory state among blacks
receiving dialysis  , dietary intake factors 97, bone mineral metabolism 97 and genetic
factors  99. Kalanter  –  Zadeh  et  al  100 showed  that  Arab  Israelis  had  a  faster
progression  to  CKD  5D  but  showed  an  overall  survival  advantage  than  their
Jewish  Israelis  CKD  5D  counterparts.  A  study  done  by  Frankenfield  et  al  101
showed  that  Mexican-American  and  Hispanics  patients  undergoing  dialysis  had
survival  advantage  compared  with  non-Hispanics  counterparts.  Wong  et  al  102
observed that Asian Americans on dialysis had a survival advantage compared to their
white counterparts. In their six year follow up study, Mesler et al 103 found that non-
white dialysis dependent patients had a survival advantage compared to Whites and
that  persisted  despite  case  mix  adjustment  using  clinical  and  demographic
information.
Genetic  factors  have  been demonstrated  to  underlie  part  of  the  risk  for  ESRD in
African  Americans  and  are  believed  to  play  a  role  in  survival  after  initiation  of
dialysis 99. The APOL 1 gene which has a high frequency among African Americans
which is believed to confer resistance against Tryponosomiasis was associated with an
increased risk of CKD104. The APOL 1 gene has been shown to predict lower age of
11
dialysis  initiation  in non-diabetic  ESRD  105.   In their  historical  cohort  of 570 808
patients with CKD stages 3 – 5 for 4.7 years non dialysis patients, Kovsedy et al 106
showed that Black patients had a survival advantage compared with White patients.
The survival advantage seen in blacks was attenuated with more advanced CKD 106.  It
is  possible  that  there  are  other  unknown race  differences  and genetic  factors  that
causes CKD resulting in different survival rates among patients with ESRD which
need to be investigated.
Conclusion
The exact underlying mechanisms of vascular calcification among CKD 5D patients
are not entirely clear. The pathophysiology of cardiovascular disease in CKD seems to
be multifaceted and poses a unique setting among heath care workers. Identification
of  at  risk groups is  crucial  in  order  to  attempt,  mitigate  or  reverse  the  effects  of
cardiovascular disease in CKD.
Clinical and epidemiological research is required to observe the trends and impact of
vascular calcification among CKD 5D patients. The information obtained is important
in  managing and mitigating  the adverse impact  of vascular  calcification  in  ESRD
patients. 
RELAVENCE AND RATIONALE FOR CONDUCTING THE STUDY 
There is paucity of data regarding the impact of vascular calcification with regards to
cardiovascular mortality, morbidity and the impact of ethnicity in Sub Saharan Africa.
Research findings will hopefully advise treatment decisions that will have a positive
impact on mortality and morbidity. 
OBJECTIVES OF THE STUDY 
Primary Objectives 
1. Determine the progression of vascular calcification in a cohort of CKD 5D
patients using the abdominal x-ray calcification scores.
2. To assess the 5-year clinical outcome of CKD 5D patients in relation to their
coronary and abdominal aortic calcification scores measured at baseline by CT
angiography and abdominal x-ray.
12
Secondary Objectives 
1. To identify the effects of vascular calcification as assessed by the pulse wave
velocity (PWV) on vascular stiffness.
2. To identify if any, differences in progression of vascular calcification among
different ethnicities. 
3. To examine the contribution of comorbid illnesses and habits in patients with
ESRD (e.g. diabetes mellitus, HIV status, hyperlipidemia, smoking) towards
progression of vascular calcification.
13
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ABSTRACT
BACKGROUND
Vascular calcification is a major risk factor for cardiovascular morbidity and mortality in patients with
end stage renal disease (ESRD). In Western countries, Blacks with ESRD appear to have lesser degrees of
vascular calcification compared to non-Blacks. However, there is no published data on the association of
ethnic differences in vascular calcification and survival in ESRD from Sub-Saharan Africa.
METHODS 
This study assessed the 5-year change in vascular calcification and mortality in a previously published
cohort of patients with ESRD. Vascular calcification was assessed by abdominal aortic calcification score
(lateral abdominal radiograph) and vascular stiffness by pulse wave velocity. 
RESULTS
Sixty-six of the original 74 participants, studied at baseline, were identified. The median age was 46.6
years (37.6-59.2) and 57.6% were women. Abdominal aortic calcification showed no progression among
Blacks [baseline range 0-5, follow up range 0-8 (p=1.00)],  but a non-significant trend to progression
among non-Blacks [baseline range 0-19,  follow up range 0-22 (p=0.066)].  Black  participants  did  not
display a survival advantage (p=0.870).  Overall, sepsis was the most common cause of mortality (64% of
those with an identifiable cause of death).   Non-Blacks had higher parathyroidectomy rates than Blacks
with 9/30 cases compared to 2/36 (p=0.036). After adjustment for parathyroidectomy at follow up, the
odds  ratio  of  having  abdominal  vascular  calcification  score  of  ≥1  amongst  non-Blacks  was  8.6-fold
greater compared to Blacks (p= 0.03). Central aortic systolic pressures (CASP) and pulse wave velocities
(PWV) were higher in the study population than age matched normative values. At follow up, a positive
correlation (r=0.5) was observed between PWV and abdominal aortic calcification (p=0.047).  Elevated
baseline coronary artery calcification score and FGF-23 level at baseline were not associated with a
difference in mortality. 
CONCLUSION
There was no significant progression in vascular calcification among Blacks.  After adjusting for increased
parathyroidectomy rates, there was a greater progression of vascular calcification amongst non-Blacks
compared to Blacks highlighting possible ethnic differences in calcium phosphate metabolism in patients
with ESRD. The lack of vascular calcification progression in Blacks was not however associated with
improved survival, but the sample size was small.
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INTRODUCTION
Chronic Kidney Disease (CKD) is a major public health problem in South Africa (SA) due to the
high  prevalence  of  hypertension,  diabetes  and  HIV.1,2,3 A  population  based  sample  study
conducted in Bellville, Cape Town using the Modification of Diet in Renal Disease equation to
calculate the estimated glomerular filtration rate, demonstrated a high prevalence of CKD stage
3 - 5 of 7.6% (with ethnicity correction) and 23.9 % (without ethnicity correction).4 CKD has a
higher cardiovascular(CV)  mortality due to traditional  risk  clustering  of  CV as well  as non-
traditional CV risk factors, including vascular calcification of the tunica media. 5
Various surrogate markers have been used to assess vascular health in patients with CKD.6 The
extent of coronary artery calcification has shown to be a powerful clinical predictor of long term
prognosis in asymptomatic CKD patients .7 Furthermore, Fibroblast Growth Factor 23 (FGF-23) is
positively  associated  with  left  ventricular  hypertrophy  (LVH),  endothelial  dysfunction,
progression  of  CKD and a  higher  mortality.8,9 Pulse  wave  velocity  (PWV)  and central  aortic
systolic  pressure  (CASP)  can  be  used  non-invasively  to  measure  vascular  health.9 In  CKD,
regardless of the stage, patients have higher PWV level compared to controls with preserved
renal function.10 Blacher et al 11 showed that, in patients with ESRD, increased PWV was a strong
independent predictor of  CV and all-cause mortality.  Vascular   calcification,  atherosclerosis,
changes  in  collagen  and  elastin,  and  uremia  are  all  thought  to  result  in  increased  arterial
stiffness in CKD.12
Ethnicity may also play a role in the development of vascular calcification. Numerous studies in
developed countries describes  slower progression of vascular calcification in Blacks compared
to  non-Blacks.13,14. Freercks et al 15 showed that Black South African dialysis patients appeared
to be protected from vascular calcification. The median coronary calcium score among Blacks
was  0  (IQR 0)  and 66 non-Blacks  (IQR 383 p  <  0.01)  15.  Even after  adjustment,  Black  race
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remained a negative predictor for coronary calcification 15. There is a paucity of other data on
ethnic variations in vascular calcification in  sub-Saharan Africa.  This apparent advantage for
Blacks  on  dialysis  may  be  due  to a  lower  pro-inflammatory  state,  dietary  intake,  genetic
factors and variations in bone mineral  metabolism.  7,10,16 Differences in ethnic  bone mineral
metabolism regulation, bone mass acquisition and architecture  are well described.16-22 Black
subjects with end stage renal disease (ESRD) have been shown to have a more favorable bone
density and bone architecture, less calcium renal excretion, elevated gastrointestinal calcium
absorption, lower 25-hydroxy vitamin D and higher levels of parathyroid hormone (PTH) than
their non-Black counterparts. 17,18,19 
The present study is a five year follow up, single centre study of patients initially recruited to
investigate vascular calcification in dialysis-dependent patients.15 The study aimed to assess the
progression  of  vascular  calcification  and  ensuing  clinical  sequelae  as  well  as  the  possible
survival  advantage  of  Blacks  on  dialysis.  The  study  protocol  was  approved  by  the  Human
Research Ethics Committee of the University of Cape Town (HREC REF: 048/2016). 
METHODS
Of the 74 patients recruited in the initial study, 66 were traced. All study participants were over
18 years old and provided written informed consent. Testing was conducted on the dialysis
patients  after completion of  dialysis  and on pre-scheduled clinic  appointment visits  in non-
dialysis  dependent  patients.  The  cohort’s  study  methods  have  been  described  in  detail
elsewhere  20,  but  included:  baseline  anthropometry,  electrocardiogram  (ECG),  abdominal
calcification scores  (calculated  from lateral  abdominal  radiograph),  coronary  calcium scores
(CCS)  calculated  from  a  cardiac  computer  tomography,  and  FGF-23  levels.  Medical  data
including smoking habits and dialysis modality were captured. The following investigations were
done at the 5-year follow-up visit: anthropometry, lateral abdominal radiograph, ECG, and PWV
and CASP measurement using the AtCor Medical SphygmoCor XCEL® device. 
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All  anthropometric  measurements  were conducted by one investigator  (KS).  The peritoneal
dialysis patient was weighed after drainage of the dialysate.  All  haemodialysis patients had
their weights measured post dialysis. Abdominal truncal obesity was defined using the African
normative values of waist circumference of male ≥ 94 cm and females ≥80 cm.21
All  resting ECGs were performed using standard calibration and analyzed by one investigator
(SK). The Sokolow-Lyon (SL) and Cornell Criteria, as per European Society Cardiology guidelines,
were used to diagnose left ventricular hypertrophy (LVH)22 and were corrected for body mass
index (BMI).23 
Abdominal radiographs were taken using a standardized technique.  15 Scoring of calcification
was assessed as per 24-point scale using the validated method described by Kaupilla et al.  24
The same investigator  (RF)  who conducted the abdominal  calcification scoring in  the initial
study was blinded and scored all the radiographs done at follow up.
Statistical Analysis
The data were entered into a RedCap database and cleaned using pivot tables in Microsoft
Excel  before  being  exported  to  STATA  14  (Stata  Corp,  College  Station,  Texas)  for  analysis.
Statistical  tests  were  performed  according  to  whether  the  variable  was  continuous  or
categorical.  Continuous  data  are  expressed  as  mean  values  ±  SD  or  median  values  (IQR)
depending on the normality of data. For categorical data the χ2 test or Fisher exact test and the
Z  test  were  used  to  test for  a  statistical  difference  between  variables  and  proportions,
respectively. The Mann – Whitney and Student t test were used to test the association between
continuous and categorical variables. Participants of African descent were classified as Blacks.
The rest were classified as non-Blacks for analysis.
The survival of Blacks versus non-Blacks at 5 years was analyzed using Kaplan Meir curves. The
difference in progression of vascular calcification among Blacks and non-Blacks at baseline and
follow-up was analyzed using the paired t-tests and sign-rank paired test based on normality.
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PWV measurements were not undertaken in the initial study. Using normative values of PWV
published  in  a  South  African  study  25,  the  effects  of  vascular  calcification  on  PWV  were
identified. A BPro watch device (HealthSTATS, Singapore) was used to measure the CASP in the
initial  study.  The  five-year  clinical  outcome  in  relation  to  calcium  scores  at  baseline  was
analysed using the Student’s t-test.  
RESULTS
Baseline and follow-up characteristics of the population are presented in table 1. At baseline
and follow up 57.6% of participants were women (n=38) and 54.5% were Black (n=36). The
majority of patients traced were still alive 63.6% (n=42). Among participants that were alive:
57.1% (n=24) had been transplanted, 40.5% (n=17) were on hemodialysis and one patient was
on  peritoneal  dialysis.  Non-Blacks  had  progressive  abdominal  calcification  approaching
significance  [baseline  range  0-5,  follow  up  range=0-8  (p=0.066)]  compared  to  Blacks  who
showed no progression [baseline range=0-19, follow up range 0-22 (p=1.00)].  Non-Blacks had
higher  parathyroidectomy  rates  of  9/30  cases  compared  to  2/36  cases  of  Black  patients
(p=0.036). The odds ratio of having abdominal vascular calcification score of ≥1 amongst non-
Blacks at follow up was 8.6 fold greater than a similar calcification score amongst Blacks, after
having adjusted for parathyroidectomy (p=0.031). At follow up, a positive correlation (r=0.3)
was observed between PWV and abdominal vascular calcification (p=0.04). Significant weight
gain among all participants at follow up compared to baseline was observed  (27.1±7.1kg/m2
versus 24.4±4.2kg/m2 respectively; p<0.015). There was a regression in LVH using both the SL
score corrected for BMI (p<0.001) and Cornell  product corrected for BMI (p=0.027).  In our
study  group  12.1%  (n=4)  of  transplanted patients  during  follow  up  developed  new  onset
diabetes after transplantation (NODAT). Infections were the most common cause of morbidity
(50.8%) followed by: ischemic heart disease (38.5%), gout (10.8%), NODAT (6.0%), peripheral
vascular  disease  (3.1%),  cerebrovascular  accidents  (3.1%),  peripheral  neuropathy  (3.1%),
depression (1.5%) and vertebral fractures (1.5%).
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There was no difference in survival by ethnicity (p=0.870) (Figure 1). The renal replacement
modality  of  participants  who  had  died  at  follow-up  included:  38%  transplant  (n=9),  16%
peritoneal dialysis (n=4), 38% hemodialysis (n=9) and 8% had no data (n=2). Overall, sepsis was
a major cause of mortality in our study group, seen in 9 of 14 participants (64%) in whom a
cause of death could be identified. More participants with a CCS≥1 at baseline were on dialysis
than  had  been  transplanted  at  follow  up  (p=0.035)  (Table  3).  Participants  with  coronary
calcification had a higher numerical probability of dying (43.3% versus 30.6%; p=0.213). 
Table 1:   Characteristics of the study population at baseline and follow-up 
CHARACTERISTIC BASELINE (74) FOLLOW-UP (66) P-VALUE
AGE, median (IQR) 42.1 (32.7 – 49.3) 46.6 (37.6—59.2) <0.0001 °
WOMEN n, % 42 (56.8) 38 (57.6) 0.922 †
BLACKS n, % 40 (54.1) 36 (54.5) 0.954 †
RENAL REPLACEMENT STATUS, n (%)
HD
PD
Transplant
28 (42.4)
5 (7.6)
33 (50.0)
ALIVE, n (%)
All
HD
PD
Transplant
42 (63.6) 
17 (40.5) 
1 (2.4)
24 (57.1) 
BMI
All
Transplanted
Dialysis
24.3 (±4.1)
24.6 (±3.4)
24.1 (±4.7)
27.1 (±7.1)
27.4 (±8.3)
26.6 (±5.1)
0.015 ‡
0.100 ‡
0.008 ‡
DM INCIDENCE
All
Transplant
Dialysis
Blacks 
Non-Blacks
4 (6.0)
4 (12.1)
0
4 (11.1)
0
0.131 †
ABDO CALC (mean, SD)(mode)
Blacks
Non-Blacks
0.4 (±1.3)
4.9 (±7.1)
0 - 5
0 - 19
0.6 (±1.9)
5.6 (±6.9)
0 - 8
0 - 22
1.000 ‡
0.066 ‡
LVH
SL Score corrected for BMI
(mm*kg,m2)
SL Score corrected for BMI Blacks 
SL Score for BMI Non-Blacks 
939 (±376)
926 (±364)          
 954 (±407)
671 (±280)
696 (±334)
666 (±215)
<0.001 ‡
0.068 ‡
0.002 ‡
0
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Figure 1: Kaplan – Meier estimates of patients who had died at follow-up according to race
All  females  and 85% of  male  participants  had  truncal  obesity  at  follow up.  21 The  median
abdominal  circumference of  males  was 96.5cm (IQR:  93–102.5cm),  2.7% above  the African
normative values. Females had a median abdominal circumference of 101.5cm (IQR: 90 -108
cm),  27%  above  normative  African  values  .  There  was  no  difference  in  abdominal  obesity
between Blacks and non-Blacks (p=0.254). The median BMI at follow up for participants who
developed NODAT was 23.4kg/m2 (19.5-27.2) compared to those who did not develop NODAT
27.5kg/m2  (23.7-31.4)  (p=0.095).  A  mean  weight  gain  of  1.1kg  (1.5)  was  observed  among
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participants who developed NODAT compared to 4.8kg (3.4) (p=0.072) in participants who did
not develop NODAT. In our study group, only Black participants developed NODAT (Table 1). 
At baseline non-Blacks had a higher numerical median FGF-23 compared to Blacks (p=0.513).
Study participants who had higher FGF-23 at baseline had a higher probability of death that
approached significance (p=0.075). FGF-23 could not be measured at follow up. 
Using normative values among an age-stratified South African population, higher median values
of  PWV were observed among participants  in the age groups below 60 years compared to
normative values (Table 2).24 A positive correlation between PWV and abdominal calcification
was observed at follow up (r=0.5, p=0.047) Baseline CASP was not a predictor of outcome at
follow up,  baseline  mean CASP was 134.5mmHg (±24.1)  for  participants  alive  at  follow up
compared  to  baseline  CASP  of  132.1mmHg  (±29.2)  in  those  who  had  died  at  follow  up
(p=0.723).
Table 2  : Pulse wave velocity at follow up compared to African normative values  
Pulse wave velocity
Males & Females
20-29 years
30-39 years
40-49 years
50-59 years
60-69 years
Normative Values24
Value 50th (10th 90th)
6.1 (5.3, 7.10)
6.4 (5.2,8.00)
6.9(5.9,8.60)
8.1(6.3,10.0)
10.3(9.7,13.1)
Participants
Value 50th (n) (10th 90th)
6.6 (7)             (5.3 ,8.6)
7.3 (7)             (4.9, 13.1)
8.1 (14)           (6.3, 10.4)
8.8 (5)            (6.5, 12.3)
8.1 (1)
Table 3:   Patient characteristics at follow up, stratified by baseline coronary calcium scores (CCS) 
CHARACTERISTIC CCS = 0 CCS ≥ 1 P-VALUE
Current status, n (%)
Haemodialysis
Peritoneal dialysis
Transplant
12/36 (33.3)
1/36 (2.8)
23/36 (63.9)
15/27 (55.6)
4/27 (14.8)
8/27 (29.6)
0.015 ®
Vital status, n (%)
Alive
Dead
25/36 (69.4)
11/36 (30.6)
14/27 (51.9)
13/27 (48.1)
0.155 ¥
Complications, n (%)
Cardiovascular diseases 14/36(38.9) 16/30(53.3) 0.241 ¥
33
Parathyroidectomy
Gout
Infections
Peripheral neuropathy
Depression
Vertebral fracture
4/36 (11.1)
3/36 (8.3)
16/36 (44.4)
1/36 (2.8)
1/36 (2.8)
1/36 (2.8)
5/30 (16.7)
4/30 (13.3)
17/30 (56.7)
1/30 (3.3)
0
1/30 (3.3
0.721 ®
0.511 ®
0.323 ¥
-
-
SL score corrected for BMI, mean (±SD) 720.3 (±336) 625.1 (±193) 0.289 ‡
‡ Student’s t-test, ¥ Chi-square, ® Fishers exact test
Discussion
To  our  knowledge,  this  is  the  first  follow  up  study  in  sub-Saharan  Africa  assessing  the
progression of vascular calcification among ESRD patients. Due to resource limitations, stringent
criteria are applied to assess eligibility for state funded dialysis and subsequent transplantation.
For example, patients >60 years and diabetics >50 years, morbidly obese patients and diabetics
with significant target organ disease are not accepted. This explains our relatively young, non-
diabetic, non-obese study population (Table 1).
In this study we found that non-Black patients had a trend to greater progression of vascular
calcification. While the sample size is small,  this is  consistent with numerous studies in the
developed world that have shown that ethnicity is a risk factor for the progression of vascular
calcification with slower progression among Blacks.26,27 
Blacks in our study group had lower parathyroidectomy rates. However, studies in the USA have
found higher parathyroidectomy rates among Blacks compared to non-Blacks. 28,29 This contrary
finding is not explained and could be confounded by the small sample size.  
BMI significantly increased during the study period, likely due to the effects of transplantation
as well as improved nutrition after the continuation of effective dialysis and amelioration of
uremic symptoms. All females and 85% of males met African criteria for abdominal obesity. 21
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Obesity is regarded as a risk factor for cardiovascular disease, reduced patient survival, graft
rejection and loss as well as death among patient’s organ transplant recipients.  30,31,32 NODAT
developed in 12.1% of the patients who had received a kidney transplant and they were all
Black (p=0.131). This finding is consistent with published data where NODAT has been reported
to occur in 2-53 % of all solid organ transplants and is a serious and common complication of
kidney  transplantation.  33 34 In  our  group,  weight  gain  was  not  a  risk  factor  of  developing
NODAT: 1.1kg (±1.5) vs 4.8kg (±3.4) p=0.072. Known risk factors for developing NODAT are
multifactorial and include race, age of recipient, male sex, family history of diabetes mellitus,
genetics, rejection history and type of immunosuppressant therapy prescribed. 33 
LVH is a poor outcome predictor among patients on hemodialysis and in transplant patients. 35,36
The significant  regression in LVH among dialysis  and transplant  patients at  follow up could
possibly be ascribed to BP control and management of hyperparathyroidism.37,38 Left ventricular
remodeling is thought to occur after renal transplant, effecting systolic and diastolic function,
but the evidence is not uniform. 39 After a follow up of 2 years, Rajan et al observed that kidney
transplant had no association with significant regression of left ventricular mass index using
cardiac  magnetic  resonance  imaging  compared  to  patients  on  the  waiting  list.40 However,
others report that renal transplant is associated with significant LVH regression.  41,  42 The LVH
regression  among  our  study  participants  was  not  found  to  be  solely  due  to  renal
transplantation. 
Studies in the developed world have shown a ‘survival paradox’ in Blacks compared to non-
Blacks. 43,44,45 We did not find a difference in survival in Blacks in our cohort despite the absence
of progressive vascular calcification in them. Recent studies in the USA have suggested that this
apparent survival advantage is less significant in age groups above 40 years.14  A larger sample
size would be needed to accurately assess this possible survival advantage in our predominantly
young, Black African dialysis population. However, among participants with a known cause of
death, the majority died of sepsis (64%) which is consistent with studies done in Brazil and sub-
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Saharan Africa.46, 47  This is likely to have obscured any difference attributable to cardiovascular
causes.
High levels of vascular stiffness are associated with CKD and dialysis dependency 48, 49.  Higher
PWV values in participants at follow up, compared to available normative age-stratified ranges,
were found. 
The study should be viewed in the context of its potential limitations. The sample size is small
and medical data was collected from patient files thus some data could have been missing or
not documented. The selection criteria for participation in the state dialysis program is rigorous
due to limitation of resources and most patients are from a low-socio economic background;
this could affect the replicability of these results in other cohorts 50 .  Although it was a single
center study this  was a longitudinal  study with a strong follow up rate  of  87.8%.The same
investigators  assessed certain  clinical  parameters  at  baseline  and follow up which included
abdominal X-rays and ECGs to reduce inter-observer variability.  
In conclusion, the study describes a majority of less than 50 years old, Black, ESRD population in
a resource constrained setting.  Increased vascular  stiffness and metabolic  risk  factors,  were
highlighted and sepsis was a major cause of death among all participants. The differences in
coronary calcification progression and parathyroidectomy rates between Blacks and non-Blacks
suggest ethnic variances in mineral metabolism among patients with ESRD. Further research, in
a  larger  cohort,  is  needed  to  understand  these  differences  and  inform  and  improve
management of all patients with CKD. 
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